marijuana stock news

Pazoo Begins Generating Consulting Based Revenue With The Signing Of Operational Advisory Agreement For Denver Colorado Testing Lab

Pazoo, Inc. (OTC Pinks: PZOO) (German WKN#: A1J3DK), is pleased to announce that Pazoo is now generating revenue under a consulting agreement from the operations of a marijuana testing lab. Pazoo last week signed the operational advisory agreement directly with Harris Lee Colorado, LLC (HLCO) for the Denver Colorado marijuana testing laboratory.

Pazoo, through wholly-owned subsidiary Harris Lee, LLC will begin to earn a fee per test once the transfer of ownership of the Denver testing lab is completed to Harris Lee Colorado. Pazoo currently is also earning a consulting fee during this interim step of HLCO as being the advisory manager and advisor on the proper marketing, sales, testing and overall management of the facility. The final approval from the MED for the complete transfer of the license is expected soon.

David Cunic, CEO of Pazoo, commented “We are very excited to have this consulting and advisory deal signed and to begin generating revenue off of our marijuana testing operations.  We are also very happy about our CK Distribution, LLC sales team out in Colorado being in full force starting to bring in new clients.  As for MA & Associates, we are very excited to be partaking and having a booth at the upcoming Marijuana Business Conference and Expo from November 11-13 in Las Vegas.”

About Pazoo, Inc.:

Pazoo, Inc. is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly owned subsidiaries, Harris Lee and MA & Associates, Pazoo provides industry leading laboratory testing of cannabis. Pazoo is licensed to test cannabis in Nevada, with a focus on expansion into other states. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its websitewww.pazoo.com, and features industry experts from both the health and wellness arena and the pet industry. Lastly, our newly formed wholly owned subsidiary CK Distribution LLC, provides the marketing and sales agent for the distribution of non-controlled hemp products throughout the USA. Non-controlled hemp products are the items utilized by the industry that support grow facilities, infusion companies and dispensaries.

Safe Harbor Statement:

This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/pazoo-begins-generating-consulting-based-revenue-with-the-signing-of-operational-advisory-agreement-for-denver-colorado-testing-lab-300174611.html


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$AFI: Abbattis Bioceuticals Claim Against Affinor Growers is Unlawful and Dismissed in Court

Abbattis Bioceuticals Unlawful Claim Against Affinor Growers Dismissed Without Prejudice in Court…

Wayland Group (MRRCF) Addresses Transaction with ICC International Cannabis Corp.

Wayland Addresses Transaction with ICC International Cannabis Corp. Wayland Group (CSE:WAYL) (75M.F)…

Cara Therapeutics, Inc. (CARA) Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim…